Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 238

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 238
---
 ASU 2023-07 improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments introduce a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker (“CODM”), extend certain annual disclosures to interim periods, clarify single reportable segment entities must apply ASC 280 in its entirety, permit more than one measure of segment profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. This guidance is effective for fiscal years, beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this guidance will have on our financial statements and disclosures.

Note 3 - License, Clinical Trial and Sponsored Research Agreements

Research and Development Expenses – All Licenses

For the years ended December 31, 2023 and 2022, the Company recorded the following expense in research and development for licenses acquired:

| ​                                    
 ​                                    
 ($ in thousands)                     | ​ 
 ​ | ​                               
 For the year ended December 31, 
 2023                            |   ​ | ​ | ​    
 2022 |     ​ |
|:-------------------------------------|:--|:--------------------------------|----:|:--|:-----|------:|
| City of Hope National Medical Center | ​ | ​                               |   ​ | ​ | ​    |     ​ |
| IV/ICV                               | ​ | ​                               |   — | ​ | ​    |   125 |
| HER2                                 | ​ | ​                               |   — | ​ | ​    |   200 |
| CSL Behring (Calimmune)              | ​ | ​                               |  50 | ​ | ​    |    40 |
| Fortress Annual Stock Dividend       | ​ | ​                               | 477 | ​ | ​    | 1,109 |
| Total                                | ​ | $                               | 527 | ​ | $    |